Treatment of calcium pyrophosphate crystal deposition disease: a mini-review

Abstract

Calcium pyrophosphate crystal deposition disease is a prevalent and impactful form of crystal arthropathy. It usually targets the large joints of the extremities, significantly affecting daily life. Progression of this disease, commonly observed in older individuals and often mistaken for septic arthritis, osteoarthritis, or several rheumatic conditions, remains poorly understood. The disease can present in various forms, from asymptomatic to severe joint deformity. The primary goal of treating this disease is to firmly control inflammation, prevent joint deformities, and decisively stop attacks. Medications used to treat the disease include anti-rheumatic drugs such as non-steroidal anti-inflammatory drugs, oral, intramuscular, or intra-articular steroids, hydroxychloroquine, colchicine, methotrexate, and interleukin-1 receptor antagonists. Radiosynovectomy is a radioactive technique that effectively targets and eliminates inflamed synovium. This article highlights the importance of awareness and early intervention to manage this condition effectively.

Keywords

Calcium pyrophosphate crystal deposition disease / acute arthritis / crystals / osteoarthritis / treatment

References

[1] Pascart T, Filippou G, Lioté F, Sirotti S, Jauffret C, Abhishek A. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 2024; 6: e791-804.

[2] Kwon K, Seok H, Lee J, Kim M, Kim S, Park H, et al. Calcium pyrophosphate dihydrate deposition disease in the temporomandibular joint: diagnosis and treatment. Maxillofac Plast Reconstr Surg. 2018; 40: 19.

[3] Zhang W, Doherty M, Bardin T, Barskova V, Guerne P, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011; 70: 563- 70.

[4] McCarthy GM, Dunne A. Calcium crystal deposition diseases - beyond gout. Nat Rev Rheumatol. 2018; 14: 592-602.

[5] Williams CJ, Rosenthal AK. Pathogenesis of calcium pyrophosphate deposition disease. Best Pract Res Clin Rheumatol. 2021; 35: 101718.

[6] Franchi L, Warner N, Viani K, Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev. 2009; 227: 106-28.

[7] Ham Y, Mack H, Colville D, Harraka P, Savige J. Gitelman syndrome and ectopic calcification in the retina and joints. Clin Kidney J. 2021; 14: 2023-8.

[8] Yavorskyy A, Hernandez-Santana A, McCarthy G, McMahon G. Detection of calcium phosphate crystals in the joint fluid of patients with osteoarthritis - analytical approaches and challenges. Analyst. 2008; 133: 302-18.

[9] Ivory D, Velázquez CR. The forgotten crystal arthritis: calcium pyrophosphate deposition. Mo Med. 2012; 109: 64-8.

[10] Rosales-Alexander JL, Aznar JB, Magro-Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatol. 2014; 6: 39-47.

[11] Yates KA, Yoshida K, Xu C, Lyu H, Norvang V, Solomon DH, et al. Acute Calcium Pyrophosphate Crystal Arthritis Flare Rate and Risk Factors for Recurrence. J Rheumatol. 2020; 47: 1261-6.

[12] Resnick D, Williams G, Weisman MH, Slaughter L. Rheumatoid arthritis and pseudo-rheumatoid arthritis in calcium pyrophosphate dihydrate crystal deposition disease. Radiology. 1981; 140: 615-21.

[13] Lomax A, Ferrero A, Cullen N, Goldberg A, Singh D. Destructive pseudo-neuroarthropathy associated with calcium pyrophosphate deposition. Foot Ankle Int. 2015; 36: 383-90.

[14] Oka A, Okazaki K, Takeno A, Kumanomido S, Kusunoki R, Sato S, et al. Crowned Dens Syndrome: Report of Three Cases and a Review of the Literature. J Emerg Med. 2015; 49: e9-13.

[15] Flood R, Stack J, McCarthy G. An Update on the Diagnosis and Management of Calcium Crystal Disease. Curr Rheumatol Rep. 2023; 25: 145-51.

[16] Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK. Management of calcium pyrophosphate crystal deposition disease: A systematic review. Semin Arthritis Rheum. 2021; 51: 84-94.

[17] Stack J, McCarthy G. Calcium pyrophosphate deposition (CPPD) disease - Treatment options. Best Pract Res Clin Rheumatol. 2021; 35: 101720.

[18] Zhang W, Doherty M, Pascual E, Barskova V, Guerne P, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011; 70: 571-5.

[19] Voulgari PV, Venetsanopoulou AI, Drosos AA. Recent advances in the therapeutic management of calcium pyrophosphate deposition disease. Front Med (Lausanne). 2024; 11: 1327715.

[20] Ho KY, Cardosa MS, Chaiamnuay S, Hidayat R, Ho HQT, Kamil O, et al. Practice Advisory on the Appropriate Use of NSAIDs in Primary Care. J Pain Res. 2020; 13: 1925-39.

[21] Leung YY, Hui LLY, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45: 341-50.

[22] Spilberg I, McLain D, Simchowitz L, Berney S. Colchicine and pseudogout. Arthritis Rheum. 1980; 23: 1062-3.

[23] Tabatabai MR, Cummings NA. Intravenous colchicine in the treatment of acute pseudogout. Arthritis Rheum. 1980; 23: 370-4.

[24] Nashel DJ. Intravenous administration of colchicine. Arthritis Rheum. 1981; 24: 1215-6.

[25] Abhishek A, Tedeschi SK, Pascart T, Latourte A, Dalbeth N, Neogi T, et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Ann Rheum Dis. 2023; 82: 1248-57.

[26] Stack J, Ryan J, McCarthy G. Colchicine: New Insights to an Old Drug. Am J Ther. 2015; 22: e151-7.

[27] Hodgens A, Sharman T. Corticosteroids. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.

[28] Roane DW, Harris MD, Carpenter MT, Finger DR, Jarek MJ, Alloway JA, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997; 24: 1168-70.

[29] Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine. 2014; 81: 98-100.

[30] Cipolletta E, Matteo AD, Scanu A, Isidori M, Battista JD, Punzi L, et al. Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review. Clin Exp Rheumatol. 2020; 38: 1001-7.

[31] Altomare A, Corrado A, Maruotti N, Cici D, Cantatore FP. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease. Mol Biol Rep. 2021; 48: 4789-96.

[32] Andrés M, Sivera F, Pascual E. Therapy for CPPD: Options and Evidence. Curr Rheumatol Rep. 2018; 20: 31.

[33] Desmarais J, Chu C. Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center. J Rheumatol. 2019; 46: 748-50.

[34] Dumusc A, Maldonado BP, Benaim C, Zufferey P, Aubry-Rozier B, So A. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study. Joint Bone Spine. 2021; 88: 105088.

[35] González T, Gantes M. Colchicine and pseudogout. Arthritis Rheum. 1982; 25: 1509-10.

[36] Pascual E, Andrés M, Sivera F. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease? Arthritis Res Ther. 2015; 17: 89.

[37] Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997; 23: 327-31.

[38] Chollet-Janin A, Finckh A, Dudler J, Guerne P. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007; 56: 688-92.

[39] Finckh A, Carthy GMM, Madigan A, Linthoudt DV, Weber M, Neto D, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014; 16: 458.

[40] Josefina M, Ana CJ, Ariel V, Silvio AA. Development of pseudogout during etanercept treatment. J Clin Rheumatol. 2007; 13: 177.

[41] Latourte A, Ea H, Frazier A, Blanchard A, Lioté F, Marotte H, et al. Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. Ann Rheum Dis. 2020; 79: 1126-8.

[42] Sarkozi AM, Nemeth-Csoka M, Bartosiewicz G. Effects of glycosaminoglycan polysulphate in the treatment of chondrocalcinosis. Clin Exp Rheumatol. 1988; 6: 3-8.

[43] Disla E, Infante R, Fahmy A, Karten I, Cuppari GG. Recurrent acute calcium pyrophosphate dihydrate arthritis following intraarticular hyaluronate injection. Arthritis Rheum. 1999; 42: 1302-3.

[44] Luzar MJ, Altawil B. Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum. 1998; 41: 939-40.

[45] Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983; 42: 106-7.

[46] Florentin M, Elisaf MS. Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol. 2012; 1: 151-4.

[47] Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. Lancet. 1981; 2: 1243-6.

[48] Cowley S, McCarthy G. Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review. Open Access Rheumatol. 2023; 15: 33-41.

[49] Cheung HS, Kurup IV, Sallis JD, Ryan LM. Inhibition of calcium pyrophosphate dihydrate crystal formation in articular cartilage vesicles and cartilage by phosphocitrate. J Biol Chem. 1996; 271: 28082-5.

[50] Iqbal SM, Qadir S, Aslam HM, Qadir MA. Updated Treatment for Calcium Pyrophosphate Deposition Disease: An Insight. Cureus. 2019; 11: e3840.